Given that PSMA is overexpressed by neovascular endothelial cells in numerous malignancies, including HCC, this provides a rationale for employing PET/CT or PET/MRI with PSMA-radioligands in tumors exhibiting low 18F-FDG uptake, thereby evaluating molecular pathways beyond glucose metabolism. This evidence concerns the gene FOLH1 and hepatocellular carcinoma.